```
Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:lfbws5

PASSWORD:
  * * * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * * *
SESSION RESUMED IN FILE 'REGISTRY' AT 10:19:26 ON 29 MAY
2007
FILE 'REGISTRY' ENTERED AT 10:19:26 ON 29 MAY 2007
COPYRIGHT (C) 2007 American Chemical Society (ACS)
COST IN U.S. DOLLARS                                  SINCE FILE
TOTAL
                                                        ENTRY
SESSION
FULL ESTIMATED COST                                    172.55
172.76

=> d his

     (FILE 'HOME' ENTERED AT 10:17:28 ON 29 MAY 2007)

     FILE 'REGISTRY' ENTERED AT 10:17:33 ON 29 MAY 2007
L1                STRUCTURE UPLOADED
L2             29 S L1
L3           2079 S L1 FULL
L4                STRUCTURE UPLOADED

=> d l4
L4 HAS NO ANSWERS
L4                STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA
OFFLINE PRINT *

Structure attributes must be viewed using STN Express query
preparation.


=>  s l4 subset=l3 full
FULL SUBSET SEARCH INITIATED 10:19:48
FULL SUBSET SCREEN SEARCH COMPLETED -     2079 TO ITERATE
```

100.0% PROCESSED 2079 ITERATIONS
151 ANSWERS
SEARCH TIME: 00.00.01

L5 151 SEA SUB=L3 SSS FUL L4

=> d scan

L5 151 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Glycine, N-[4-(2-thienylcarbonyl)benzoyl]-L-γ-glutamyl-L-cysteinyl-, bimol. (2→2')-disulfide (9CI)
MF C44 H44 N6 O16 S4

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):10

L5 151 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN [1,1'-Biphenyl]-4-propanoic acid, α-[[2-[([1,1'-biphenyl]-4-
ylsulfonyl)[(3-methyl-2-thienyl)methyl]amino]-5-chlorobenzoyl]amino]-,
(αS)- (9CI)
MF C40 H33 Cl N2 O5 S2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 151 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Glycine, N-[4-[1-[5-(4,4-dimethyl-3-oxopentyl)-4-methyl-2-thienyl]-1-
ethylpropyl]-2-methylbenzoyl]- (9CI)
MF C27 H37 N O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 151 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Propanoic acid, 2-hydroxy-3-[[[4-[[4-phenyl-5-(trifluoromethyl)-2-
thienyl]methoxy]phenyl]methyl]amino]- (9CI)
MF C22 H20 F3 N O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 151 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzenepropanoic acid, 4-methyl-β-[[4-[4-(3-pyridinylcarbonyl)-1-
piperazinyl]-3-[(2-thienylcarbonyl)amino]benzoyl]amino]- (9CI)
MF C32 H31 N5 O5 S

PAGE 1-A



PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 151 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1H-1,4-Diazepine-1-carboxylic acid, 4-[4-[[[2-carboxy-1-(3-
pyridinyl)ethyl]amino]carbonyl]-2-[(2-thienylcarbonyl)amino]phenyl]hexahydro-, 1-methyl ester (9CI)
MF C27 H29 N5 O6 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 151 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 3-Pyridinepropanoic acid, β-[[4-[4-(cyclopropylcarbonyl)-1-piperazinyl]-3-[(2-thienylcarbonyl)amino]benzoyl]amino]- (9CI)
MF C28 H29 N5 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 151 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzenepropanoic acid, β-[[4-[4-(cyclopropylcarbonyl)hexahydro-1H-1,4-diazepin-1-yl]-3-[(2-thienylcarbonyl)amino]benzoyl]amino]-4-methyl- (9CI)
MF C31 H34 N4 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 151 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Glycine, N-[4-chloro-3-[(2-thienylcarbonyl)amino]benzoyl]- (9CI)
MF C14 H11 Cl N2 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 151 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN L-Lysine, N2-[2,6-dimethyl-4-[[[1-oxo-3-(2-thienyl)-2-propenyl]amino]methyl]benzoyl]- (9CI)
MF C23 H29 N3 O4 S

Absolute stereochemistry.
Double bond geometry unknown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L5 151 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Butanoic acid, 4-(methylsulfonyl)-2-[[[5-[[[2-(2-thienyl)ethyl]amino]methyl][1,1'-biphenyl]-2-yl]carbonyl]amino]-, (2S)-
(9CI)
MF C25 H28 N2 O5 S2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> fil caplus
COST IN U.S. DOLLARS SINCE FILE
TOTAL
ENTRY
SESSION
FULL ESTIMATED COST 214.55
214.76

FILE 'CAPLUS' ENTERED AT 10:21:02 ON 29 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

strictly prohibited.

FILE COVERS 1907 - 29 May 2007 VOL 146 ISS 23
FILE LAST UPDATED: 28 May 2007 (20070528/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> d his

     (FILE 'HOME' ENTERED AT 10:17:28 ON 29 MAY 2007)

     FILE 'REGISTRY' ENTERED AT 10:17:33 ON 29 MAY 2007
L1   STRUCTURE UPLOADED
L2   29 S L1
L3   2079 S L1 FULL
L4   STRUCTURE UPLOADED
L5   151 S L4 FULL SUB=L3

     FILE 'CAPLUS' ENTERED AT 10:21:02 ON 29 MAY 2007

=> s l5
L6   44 L5

=> d ibib abs hitstr 1-44

L6   ANSWER 1 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:1206578 CAPLUS Full-text
DOCUMENT NUMBER: 145:505217
TITLE: Preparation of acrylamide derivatives as bone
                          resorption inhibitors
INVENTOR(S):   Aoki, Kazumasa; Suda, Koji; Kaneko, Toshio; Kimura,
                          Tomio
PATENT ASSIGNEE(S):   Sankyo Company, Limited, Japan
SOURCE: PCT Int. Appl., 232pp.
                          CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

     PATENT NO.   KIND   DATE   APPLICATION NO. DATE

WO 2006121095	A1	20061116	WO 2006-JP309445	20060511

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: JP 2005-140019 A 20050512

OTHER SOURCE(S): MARPAT 145:505217

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R1 = optionally substituted aryl with hydroxy, nitro, cyano, etc., optionally substituted heteroaryl with hydroxy, nitro, cyano, etc.; R2 = optionally substituted aryl with hydroxy, nitro, cyano, etc., optionally substituted heteroaryl with hydroxy, nitro, cyano, etc., optionally substituted heterocyclyl with hydroxy, nitro, cyano, etc.; X = hydroxy, alkoxy, alkoxy substituted with hydroxy, etc.] and their pharmacol. acceptable salts were prepared For example, reaction of N-[4-[2-(4-methoxyphenyl)ethoxy]benzoyl]glycine, e.g., prepared

from 4-benzyloxybenzoic acid in 4 steps, with 4-chlorobenzaldehyde followed by treatment with 2-aminoethanol afforded compound II [R = Cl]. Compound II [R = cyclopropyl] decreased the serum calcium concentration by 27.6%.

IT 915017-29-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of acrylamide derivs. as bone resorption inhibitors)

RN 915017-29-7 CAPLUS

CN Glycine, N-[4-[2-(2-thienyl)ethoxy]benzoyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:845716 CAPLUS Full-text

DOCUMENT NUMBER: 145:293345

TITLE: Preparation of N-acyl-amino acid derivatives for controlling function of GPR34 receptor as antagonists or inverse agonists

INVENTOR(S): Ito, Fumio; Kimura, Eiji; Imai, Tomomi; Mori, Masaaki; Aramaki, Yoshio; Kohara, Yasuhisa; Sugo, Tsukasa; Hayase, Yoji; Kobayashi, Hiromi; Ogi, Kazuhiro

PATENT ASSIGNEE(S): Takeda Pharmaceutical Company Limited, Japan

SOURCE: PCT Int. Appl., 597pp. CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006088246	A1	20060824	WO 2006-JP303357	20060217

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: JP 2005-41775 A 20050218
JP 2005-315146 A 20051028
OTHER SOURCE(S): MARPAT 145:293345
GI



AB There are provided agents for controlling the function of a GPR34 receptor which contain compds. represented by the formula (I) [wherein ring A represents an optionally substituted homocycle or heterocycle; P represents a bond or spacer; ring D represents an optionally substituted, monocyclic aromatic ring optionally fused to a 5- to 7-membered ring; V represents a bond or a group represented by -CR14:CR15- or -N:CR16- (wherein R14, R15, and R16 each represents hydrogen or an optionally substituted hydrocarbon group); Q represents a bond or spacer; W represents carboxy or a group biol. equivalent to carboxy], salts of the compds., or prodrugs of either. These agents are useful for the prevention and/or treatment of immune diseases, inflammatory diseases, respiratory diseases, urol. diseases (urinary system diseases), central nervous system diseases, or cardiovascular diseases. Thus, 4-(4-chlorophenyl)-3-methyl-1-benzofuran-2-carboxylic acid was condensed with Me O-benzyl-L-tyrosinate hydrochloride using 1-ethyl-3-(3- dimethylaminopropyl)carbodiimide hydrochloride and HOBt in the presence of Et3N in a 1:1 mixture of DMF and CH2Cl2 (93% yield) followed by saponification with NaOH in aqueous methanol and acidification with 1 H aqueous HCl solution to give 28% O-benzyl-N-[[6-(4-chlorophenyl)-3-methyl-1-benzofuran-2-yl]carbonyl]-L- tyrosine (II). II in vitro showed antagonist activity against human GPR34 receptor expressed in CHO cells with IC50 of ≤1 μM. Pharmaceutical tablet formulations were described.

IT 907953-46-2P 907953-47-3P 907953-48-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of N-acyl-amino acid derivs. for controlling function of GPR34 receptor as antagonists or inverse agonists)

RN 907953-46-2 CAPLUS
CN Glycine, N-[(1,1-dimethylethoxy)carbonyl]-N-[[4-(3-thienylmethoxy)phenyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 907953-47-3 CAPLUS
CN Glycine, N-[[4-(3-thienylmethoxy)phenyl]methyl]-, methyl ester,
hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 907953-48-4 CAPLUS
CN Glycine, N-[[7-(4-chlorophenyl)imidazo[1,2-a]pyridin-2-yl]carbonyl]-N-[[4-
(3-thienylmethoxy)phenyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



IT **907953-44-0P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(preparation of N-acyl-amino acid derivs. for controlling function of GPR34
receptor as antagonists or inverse agonists)
RN 907953-44-0 CAPLUS
CN Glycine, N-[[7-(4-chlorophenyl)imidazo[1,2-a]pyridin-2-yl]carbonyl]-N-[[4-
(3-thienylmethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:818237 CAPLUS Full-text
DOCUMENT NUMBER: 145:224859
TITLE: Antilymphocyte antibody induction for prevention of
transplant rejection
INVENTOR(S): Aradhye, Shreeram
PATENT ASSIGNEE(S): Novartis AG, Switz.; Novartis Pharma GmbH
SOURCE: PCT Int. Appl., 21pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006086361	A2	20060817	WO 2006-US4234	20060206
WO 2006086361	A3	20070118		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2005-651045P P 20050208

AB An immunosuppressive treatment combining a S1P receptor modulator, one or more immunosuppressive drug(s) and an antilymphocyte antibody in the course of the treatment of a transplant recipient prolongs the survival of a transplant allograft. Thus, the patients were administered (i) FTY720 5 mg given 2 to 12 h prior to renal allograft revascularization, then 2.5 mg daily, (ii) cyclosporine A 8 to 10 mg/kg/day adjusted to achieve target blood levels, and (iii) corticosteroids. The dosage regimen of the study had

a beneficial effect compared to standard immunosuppressive regimens.

IT 569684-82-8
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antilymphocyte antibody in combination with immunosuppressant and S1P receptor modulator for prevention of transplant rejection)

RN 569684-82-8 CAPLUS

CN β-Alanine, N-[[4-[[4-phenyl-5-(trifluoromethyl)-2-thienyl]methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



L6 ANSWER 4 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:677741 CAPLUS Full-text
DOCUMENT NUMBER: 145:117363
TITLE: Use of sphingosine-1-phosphate (S1P) receptor agonists for the treatment of hepatitis C virus (HCV) disorders
INVENTOR(S): Brinkmann, Volker; Feutren, Gilles
PATENT ASSIGNEE(S): Novartis AG, Switz.; Novartis Pharma GmbH
SOURCE: PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006072562	A1	20060713	WO 2006-EP3	20060102

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR,

BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE,
EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KM, KN, KP, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD,
MG, MK, MN, MW, MX,
MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT,
RO, RU, SC, SD, SE,
SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VC,
VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG,
ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM
PRIORITY APPLN. INFO.: GB 2005-20
A 20050104
OTHER SOURCE(S): MARPAT 145:117363
AB S1P receptor agonists are useful for the treatment of hepatitis C or chronic hepatitis C (HCV).
IT **569684-82-8**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(S1P receptor agonists for treatment of hepatitis C virus disorders)
RN 569684-82-8 CAPLUS
CN β-Alanine, N-[[4-[[4-phenyl-5-(trifluoromethyl)-2-thienyl]methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS

AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:277866 CAPLUS Full-text
DOCUMENT NUMBER: 144:488929
TITLE: New photoactivatable analogs of glutathione disulfide
AUTHOR(S): Bernardi, Dan; Dicko, Amadou; Kirsch, Gilbert
CORPORATE SOURCE: Laboratoire d'Ingenierie Moleculaire et Biochimie Pharmacologique, Universite Paul Verlaine-Metz, Metz, 57078/3, Fr.
SOURCE: Synthesis (2006), (3), 509-513
CODEN: SYNTBF; ISSN: 0039-7881
PUBLISHER: Georg Thieme Verlag
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 144:488929
AB New photoactivatable analogs of glutathione disulfide (GSSG) bearing new benzophenone-like photophores were synthesized by using an improved coupling reaction.
IT 887628-02-6P
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(UV absorption; preparation of photoactivatable analogs of glutathione disulfide)
RN 887628-02-6 CAPLUS
CN Glycine, N-[4-(2-thienylcarbonyl)benzoyl]-L-γ-glutamyl-L-cysteinyl-, bimol. (2→2')-disulfide (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 6 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:1123749 CAPLUS Full-text
DOCUMENT NUMBER: 143:405611
TITLE: Preparation of N,N-disubstituted β-alanines as antibacterial agents
INVENTOR(S): Boyd, Edward Andrew; Hatcher, Stuart; Czaplewski, Lloyd; Errington, Jeffrey; Brown, David
PATENT ASSIGNEE(S): Prolysis Ltd., UK
SOURCE: PCT Int. Appl., 77 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005097100	A2	20051020	WO 2005-GB1295	20050401
WO 2005097100	A3	20051208		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE,

EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN,
MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD,
SE, SG, SK, SL, SM,
SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ,
TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG,
CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT,
LU, MC, NL, PL, PT,
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: GB 2004-7861
A 20040406
OTHER SOURCE(S): MARPAT 143:405611

GI



I



II

AB Compds. I [wherein Z = COOH, ester radical; ring A, B = (un)substituted monocyclic (hetero)aryl or cycloalkyl; X = O, S, CH2; R = (un)substituted monocyclic (hetero)aryl, cycloalkyl; etc., with exclusions, and salts, hydrates or solvates thereof] were prepared for use as antibacterial agents. Many N,N-disubstituted β-alanines were given as examples. For instance, DBU-mediated Michael addition of acrylate of Wang-OH resin with 3-methylbenzylamine

followed by reductive amination with 3-phenoxybenzaldehyde in the presence of NaBH(OAc)3 and HOAc, and subsequent cleavage with TFA gave amino acid II·TFA in 80% overall yield. The tested compds. I were observed to inhibit bacterial cell division, and to produce a filamentous phenotype, i.e., having an average cell length in cultures greater than or equal to twice the average cell length in control culture. Some I showed MICs of 16-64 μg/mL against bacillus subtilis 168 by the broth microdilution method.

IT **867206-20-0P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of N,N-disubstituted β-alanines as antibacterial agents)

RN 867206-20-0 CAPLUS

CN β-Alanine, N-[(3-methylphenyl)methyl]-N-[[3-(3-thienyloxy)phenyl]methyl]-, hydrochloride (9CI) (CA INDEX NAME)



L6 ANSWER 7 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:984019 CAPLUS Full-text

DOCUMENT NUMBER: 143:279395

TITLE: Methylene amide derivatives for cardiovascular disorders

INVENTOR(S): Hooft van Huijsduijnen, Rob; Richard, Vincent
PATENT ASSIGNEE(S): Apllied Research Systems Ars Holding N. V., Neth. Antilles
SOURCE: PCT Int. Appl., 75 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005082347	A1	20050909	WO 2005-EP50823	20050225
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005216649	A1	20050909	AU 2005-216649	20050225
CA 2554919	A1	20050909	CA 2005-2554919	20050225
EP 1732534	A1	20061220	EP 2005-716814	20050225
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE,				

SI, SK, TR, AL, BA,
HR, LV, MK, YU
CN 1933827 A 20070321 CN 2005-
80008722 20050225
NO 2006004295 A 20060922 NO 2006-4295
20060922
PRIORITY APPLN. INFO.: EP 2004-100778
A 20040227
WO 2005-EP50823
W 20050225
OTHER SOURCE(S): MARPAT 143:279395
GI



I

AB The present invention is related to the use of substituted methylene amide derivs. for the treatment and/or prevention of cardiovascular disorders such as coronary obstruction and heart failure and/or prevention of endothelial dysfunction in heart failure.. A methylene amide derivative I was able to acutely restore endothelial function in mice with chronic heart failure.

IT 578022-25-0, Oxo[[4-[[[2-(2-
thienyl)ethyl]amino]carbonyl]benzyl][4-
(trifluoromethyl)benzyl]amino]acetic acid;
RL: THU (Therapeutic use); BIOL (Biological study);
USES (Uses)
(methylene amide derivs. for cardiovascular
disorders)
RN 578022-25-0 CAPLUS
CN Acetic acid, oxo[[[4-[[[2-(2-
thienyl)ethyl]amino]carbonyl]phenyl]methyl][[
4-(trifluoromethyl)phenyl]methyl]amino]- (9CI) (CA
INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 8 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:216595 CAPLUS Full-text
DOCUMENT NUMBER: 142:291367
TITLE: Compound capable of binding S1P receptor and
pharmaceutical use thereof
INVENTOR(S): Nakade, Shinji; Mizuno, Hirotaka; Ono, Takeji; Minami,
Masashi; Saga, Hiroshi; Hagiya, Hiroshi; Komiya,
Takaki; Habashita, Hiromu; Kurata, Haruto; Ohtsuki,
Kazuhiro; Kusumi, Kensuke
PATENT ASSIGNEE(S): Ono Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 255 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005020882	A2	20050310	WO 2004-JP12768	20040827
WO 2005020882	A3	20050421		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,

KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN,
MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD,
SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ,
TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG,
CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC,
NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE,
SN, TD, TG

AU 2004268455	A1	20050310	AU 2004-268455	20040827
CA 2537093	A1	20050310	CA 2004-2537093	20040827
EP 1661881	A2	20060531	EP 2004-772717	20040827
BR 2004013923	A	20061107	BR 2004-13923	20040827
CN 1874991	A	20061206	CN 2004-80032022	20040827
NO 2006001372	A	20060522	NO 2006-1372	20060327

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI,
LU, NL, SE, MC, PT,
IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK

PRIORITY APPLN. INFO.:

	JP 2003-306088
A 20030829	
	JP 2004-110573
A 20040402	
	JP 2004-169958
A 20040608	
	JP 2004-198523
A 20040705	
	WO 2004-JP12768
W 20040827	

OTHER SOURCE(S): MARPAT 142:291367

AB Disclosed is a compd. capable of binding sphingosine 1-phosphate receptors (S1P receptors), especially EDG-6, preferably EDG-1 and EDG-6. For example, a compound of the general formula (R1)mAnXBYCOOH (wherein A is a cyclic group; B is an optionally substituted cyclic group; X is a spacer with a main

chain of 1 to 8 atoms, etc.; Y is a spacer with a main chain of 1 to 10 atoms, etc.; and n is 0 or 1 provided that when n is 0, m is 1 and R1 is a hydrogen atom or a substituent and that when n is 1, m is 0 or an integer of 1 to 7 and R1 is a substituent, in which when m is 2 or greater, R1s may be identical with or different from each other), its salt or solvate, or a prodrug thereof is capable of binding S1P receptors (especially EDG-6, preferably EDG-1 and EDG-6) and is thus useful in the prevention and/or treatment of immunol. reaction to transplant, graft vs. host disease, autoimmune disease, allergosis, etc. For example, 3-[3-[4-(5-phenylpentyloxy)phenyl]propylamino]propanoic acid (I) was prepared, and examined for its EDG-6 receptor binding activity in in vitro. Also, a tablet containing I 10 mg/tablet was formulated.

IT **847580-22-7P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(S1P receptor-binding agents for pharmaceutical use)

RN 847580-22-7 CAPLUS

CN β-Alanine, N-[[4-[2-(2-thienyl)ethoxy]phenyl]methyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 847580-21-6
CMF C16 H19 N O3 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



L6 ANSWER 9 OF 44 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:1127319 CAPLUS Full-text
DOCUMENT NUMBER: 142:74357
TITLE: Preparation of new benzamides for use in pharmaceutical compositions as peroxisome proliferator-activated receptor γ (PPARγ) modulators
INVENTOR(S): Ferdandez Serrat, Anna; Serra Comas, Carme; Balsa Lopez, Dolors; Llebaria Soldevila, Amadeu; Farrerons Gallemi, Carles; Miquel Bono, Ignacio Jose; Catena Ruiz, Juan Lorenzo; Lagunas Arnal, Carmen; Cordomi Montoya, Arnau; Salcedo Roca, Carolina; Toledo Mesa, Natividad; Marrero Gonzalez, Pedro; Haro Bautista, Diego; Fernandez Garcia, Andres
PATENT ASSIGNEE(S): Laboratorios S.A.L.V.A.T., S.A., Spain
SOURCE: PCT Int. Appl., 113 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004110983	A2	20041223	WO 2004-EP6330	20040611
WO 2004110983	A8	20050811		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2004247389	A1	20041223	AU 2004-247389	20040611
CA 2528231	A1	20041223	CA 2004-2528231	20040611
EP 1644321	A2	20060412	EP 2004-739820	20040611
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004011412	A	20060725	BR 2004-11412	20040611
CN 1835914	A	20060920	CN 2004-80023119	20040611
JP 2006527233	T	20061130	JP 2006-515904	20040611
US 2006160894	A1	20060720	US 2005-560533	20051213
PRIORITY APPLN. INFO.:			ES 2003-1461	A 20030613
			WO 2004-EP6330	W 20040611
OTHER SOURCE(S):	MARPAT 142:74357			

GI



I

AB Benzamides, such as I [R = OH, NH2, alkoxy, alkylamino, etc.; R1 = H, alkyl, benzyl, etc.; W = alkylene, aryl substituted alkylene; Z = benzyl, biphenylmethyl, phenylalkyl, etc.], were prepared for use in the prophylactic and/or curative treatment of a condition or a disease mediated by the PPARγ. These benzamides are claimed for use in the treatment of metabolic diseases, such as non-insulin-dependent diabetes mellitus, obesity, hypercholesterolemia and other lipid-mediated pathologies, as well as for treatment of cardiovascular disease associated with metabolic syndrome, treatment of inflammation or an inflammatory processes, such as rheumatoid arthritis, atherosclerosis, psoriasis and intestinal inflammatory disease, for treatment of cancer, skin wound healing or cutaneous disorders associated with an anomalous differentiation of epidermic cells, and for treatment of bone disease, particularly osteoporosis. Thus, the L-phenylalanine derivative, (S)-PhCH2O-4-C6H4CH2CH(CO2Me)NHCOC6H4-4-OCH2C6H4-4-OPh, is an example of the target benzamides prepared The prepared benzamides were assayed for PPARγ binding affinity and were evaluated for their PPARγ agonist/antagonist functional activity.

IT **814921-03-4P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of new benzamides for use in pharmaceutical compns. as peroxisome proliferator-activated receptor γ (PPARγ) modulators)

RN 814921-03-4 CAPLUS

CN L-Tyrosine, O-(phenylmethyl)-N-[4-(3-thienylmethoxy)benzoyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.